KR102666920B1 - 인터루킨 36 수용체(il-36r)에 대한 항체 - Google Patents

인터루킨 36 수용체(il-36r)에 대한 항체 Download PDF

Info

Publication number
KR102666920B1
KR102666920B1 KR1020177032985A KR20177032985A KR102666920B1 KR 102666920 B1 KR102666920 B1 KR 102666920B1 KR 1020177032985 A KR1020177032985 A KR 1020177032985A KR 20177032985 A KR20177032985 A KR 20177032985A KR 102666920 B1 KR102666920 B1 KR 102666920B1
Authority
KR
South Korea
Prior art keywords
ser
thr
gly
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177032985A
Other languages
English (en)
Korean (ko)
Other versions
KR20180002687A (ko
Inventor
피터 바우어스
앤드류 존 맥나잇
데이비드 제이. 킹
마르코 론디
Original Assignee
아납티스바이오, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아납티스바이오, 아이엔씨. filed Critical 아납티스바이오, 아이엔씨.
Publication of KR20180002687A publication Critical patent/KR20180002687A/ko
Application granted granted Critical
Publication of KR102666920B1 publication Critical patent/KR102666920B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020177032985A 2015-04-15 2016-04-15 인터루킨 36 수용체(il-36r)에 대한 항체 Active KR102666920B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147824P 2015-04-15 2015-04-15
US62/147,824 2015-04-15
PCT/US2016/027676 WO2016168542A1 (en) 2015-04-15 2016-04-15 Antibodies directed against interleukin 36 receptor (il-36r)

Publications (2)

Publication Number Publication Date
KR20180002687A KR20180002687A (ko) 2018-01-08
KR102666920B1 true KR102666920B1 (ko) 2024-05-20

Family

ID=57126337

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177032985A Active KR102666920B1 (ko) 2015-04-15 2016-04-15 인터루킨 36 수용체(il-36r)에 대한 항체

Country Status (14)

Country Link
US (4) US10526410B2 (https=)
EP (2) EP3283110B1 (https=)
JP (4) JP6913026B2 (https=)
KR (1) KR102666920B1 (https=)
CN (2) CN115925932A (https=)
AU (1) AU2016248208B2 (https=)
CA (1) CA2982555A1 (https=)
DK (1) DK3283110T3 (https=)
ES (1) ES2914243T3 (https=)
MX (2) MX2017013080A (https=)
PL (1) PL3283110T3 (https=)
RU (1) RU2745898C2 (https=)
SG (1) SG11201708061TA (https=)
WO (1) WO2016168542A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
EP3400962A1 (en) * 2017-05-09 2018-11-14 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibitors of il-38 for use in treating and/or preventing cancer in a subject
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2019234478A1 (en) * 2018-03-14 2020-08-20 Boehringer Ingelheim International Gmbh Use of anti-IL36R antibodies for treatment of inflammatory bowel disease
CA3093692A1 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
IL278267B2 (en) * 2018-07-16 2025-02-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
MX2021000566A (es) * 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
CN110818796B (zh) * 2018-08-09 2022-11-08 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
US11884719B2 (en) 2018-12-21 2024-01-30 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
EP3902604A1 (en) * 2018-12-27 2021-11-03 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of palmoplantar pustulosis
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
BR112021016198A2 (pt) * 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
AU2020325315A1 (en) 2019-08-07 2022-03-24 Aqualung Therapeutics Corp. Anti-NAMPT antibodies and uses thereof
JP7811772B2 (ja) * 2019-12-05 2026-02-06 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP4182022A1 (en) * 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
JP2023536851A (ja) * 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
WO2022192531A2 (en) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
EP4370550A1 (en) 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130236471A1 (en) 2011-11-16 2013-09-12 Boehringer Ingelheim Gmbh Anti il-36r antibodies
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20140271627A1 (en) 2013-03-12 2014-09-18 Declmmune Therapeutics, Inc. Humanized, anti-n2 antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO2001057219A2 (en) 2000-02-02 2001-08-09 Schering Corporation Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
MX2009002456A (es) 2006-09-08 2009-03-20 Amgen Inc Variantes de la familia il-1.
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
ES2668104T3 (es) * 2011-12-28 2018-05-16 Immunoqure Ag Procedimiento de aislamiento de anticuerpos humanos
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
AU2019234478A1 (en) 2018-03-14 2020-08-20 Boehringer Ingelheim International Gmbh Use of anti-IL36R antibodies for treatment of inflammatory bowel disease
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
US11884719B2 (en) 2018-12-21 2024-01-30 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
EP3902604A1 (en) 2018-12-27 2021-11-03 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of palmoplantar pustulosis
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
WO2020233571A1 (zh) 2019-05-20 2020-11-26 上海一宸医药科技有限公司 一种双特异性分子及其制备与用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20130236471A1 (en) 2011-11-16 2013-09-12 Boehringer Ingelheim Gmbh Anti il-36r antibodies
US20140271627A1 (en) 2013-03-12 2014-09-18 Declmmune Therapeutics, Inc. Humanized, anti-n2 antibodies

Also Published As

Publication number Publication date
BR112017022086A2 (pt) 2018-07-03
SG11201708061TA (en) 2017-10-30
US12391761B2 (en) 2025-08-19
RU2017139481A (ru) 2019-05-15
JP7721585B2 (ja) 2025-08-12
HK1250941A1 (en) 2019-01-18
US10526410B2 (en) 2020-01-07
RU2017139481A3 (https=) 2019-09-19
US11130814B2 (en) 2021-09-28
CN107847590A (zh) 2018-03-27
JP7212098B2 (ja) 2023-01-24
US20200087408A1 (en) 2020-03-19
CA2982555A1 (en) 2016-10-20
WO2016168542A1 (en) 2016-10-20
ES2914243T3 (es) 2022-06-08
KR20180002687A (ko) 2018-01-08
AU2016248208B2 (en) 2022-03-24
RU2745898C2 (ru) 2021-04-02
US20180094065A1 (en) 2018-04-05
EP3283110A1 (en) 2018-02-21
JP2025163120A (ja) 2025-10-28
NZ736535A (en) 2024-08-30
US20210388095A1 (en) 2021-12-16
CN107847590B (zh) 2022-07-26
EP4176900A1 (en) 2023-05-10
DK3283110T3 (da) 2022-05-23
JP2023040236A (ja) 2023-03-22
HK1252009A1 (zh) 2019-05-10
EP3283110B1 (en) 2022-04-20
CN115925932A (zh) 2023-04-07
PL3283110T3 (pl) 2022-06-27
JP6913026B2 (ja) 2021-08-04
AU2016248208A1 (en) 2017-11-09
EP3283110A4 (en) 2019-02-27
MX2017013080A (es) 2018-02-09
JP2018512157A (ja) 2018-05-17
US20260022181A1 (en) 2026-01-22
JP2021118710A (ja) 2021-08-12
MX2023001791A (es) 2023-03-10

Similar Documents

Publication Publication Date Title
JP7721585B2 (ja) インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
US11999783B2 (en) Method of treating autoimmune disease with antibodies against IL-33
US10836824B2 (en) Antibodies directed against lymphocyte activation gene 3 (LAG-3)
HK40086847A (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1250941B (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1252009B (en) Antibodies directed against interleukin 36 receptor (il-36r)
BR112017022086B1 (pt) Anticorpo isolado de receptor de interleucina-36 ou fragmento de ligação ao antígeno do mesmo, composição seus usos
HK1231082B (en) Antibodies directed against interleukin-33 (il-33)
HK1231082A1 (en) Antibodies directed against interleukin-33 (il-33)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171114

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230703

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231130

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240318

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240513

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240514

End annual number: 3

Start annual number: 1

PG1601 Publication of registration